1.
Albuminuria in chronic heart failure: prevalence and prognostic importance
by Jackson, Colette E, MB ChB
The Lancet (British edition), 2009, Vol.374 (9689), p.543-550
2.
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
by Granger, Bradi B
The Lancet (British edition), 2005, Vol.366 (9502), p.2005-2011
3.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and mo...
by Ducharme, Anique
The American heart journal, 2006, Vol.152 (1), p.86-92
4.
Effect of Baseline Cognitive Function and Antihypertensive Treatment on Cognitive and Cardiovascular Outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE)
by Skoog, Ingmar
American journal of hypertension, 2005, Vol.18 (8), p.1052-1059
5.
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multi...
by Forns, Xavier
The Lancet infectious diseases, 2017, Vol.17 (10), p.1062-1068
6.
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme
by Hawkins, N M
Heart (British Cardiac Society), 2007, Vol.93 (1), p.59-64
7.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of...
by Wallentin, Lars, Prof
The Lancet (British edition), 2010, Vol.376 (9745), p.975-983
8.
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation
by Miller, Corey S., BA
The American journal of cardiology, 2012, Vol.110 (3), p.453-460
9.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
by Mann, Johannes FE, Prof
The Lancet (British edition), 2008, Vol.372 (9638), p.547-553
10.
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
by Böhm, Michael, Prof
The Lancet (British edition), 2017, Vol.389 (10085), p.2226-2237
11.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controll...
by Yusuf, S
The Lancet (British edition), 2008, Vol.372 (9644), p.1174-1183
12.
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabI...
by Van de Werf, Frans, MD
The American heart journal, 2012, Vol.163 (6), p.931-937.e1
13.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
by Chayama, Kazuaki
Journal of gastroenterology, 2017, Vol.53 (4), p.557-565
14.
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
by Cuchel, Marina, Dr
The Lancet (British edition), 2013, Vol.381 (9860), p.40-46
15.
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
by Motzer, Robert J, Dr Prof
The lancet oncology, 2014, Vol.15 (3), p.286-296
16.
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 tri...
by Manns, Michael, Prof
The Lancet infectious diseases, 2016, Vol.16 (6), p.685-697
17.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
by Diéras, Véronique
The lancet oncology, 2020, Vol.21 (10), p.1269-1282
18.
Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
by Younossi, Z. M.
Alimentary pharmacology & therapeutics, 2015, Vol.41 (6), p.544-563
19.
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
by Kohli, Anita, MD
The Lancet infectious diseases, 2015, Vol.15 (9), p.1049-1054
20.
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
by Chaturvedi, Nish, Prof
The Lancet (British edition), 2008, Vol.372 (9647), p.1394-1402
